Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IO170
- Development stage
- Phase 1
- Lead developer
- IO Biotech
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
IO170 is a **TGF-β peptide vaccine** developed by IO Biotech. It targets Transforming Growth Factor Beta (TGF-β), a key immune-suppressive factor in solid tumors. The vaccine has shown significant tumor growth reduction in pancreatic adenocarcinoma and prostate cancer models by inducing robust immune responses and reshaping the tumor microenvironment without systemic toxicity[1][2][4].
- Other names
- TGF-beta-15 peptideTGF-beta15 peptideTGF-beta 15 peptideTGF-beta-15 peptide vaccineTGF-beta15 peptide vaccineTGF-beta 15 peptide vaccine
02
Targets
Transforming growth factor beta-expressing cells via transforming growth factor beta-derived peptide-MHC complexes
Beyond the preview
Go deeper on IO170.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IO170.